{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:40:14Z","timestamp":1789609214548,"version":"build-2803163510"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Probes"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.mcp.2014.11.007","type":"journal-article","created":{"date-parts":[[2014,12,5]],"date-time":"2014-12-05T19:48:13Z","timestamp":1417808893000},"page":"54-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients"],"prefix":"10.1016","volume":"29","author":[{"given":"Francesca","family":"Rossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Newsome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7906-8002","authenticated-orcid":false,"given":"Raphael","family":"Viscidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcp.2014.11.007_bib1","first-page":"93","article-title":"Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease","volume":"81","author":"Astrom","year":"1958","journal-title":"Brain"},{"key":"10.1016\/j.mcp.2014.11.007_bib2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1086\/514083","article-title":"Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993","volume":"176","author":"Selik","year":"1997","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.mcp.2014.11.007_bib3","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000311014","article-title":"Progressive multifocal leukoencephalopathy deaths in the USA, 1979\u20132005","volume":"35","author":"Christensen","year":"2010","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.mcp.2014.11.007_bib4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrneurol.2010.164","article-title":"Progressive multifocal leukoencephalopathy and other forms of JC virus disease","volume":"6","author":"Brew","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.mcp.2014.11.007_bib5","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.mcp.2014.11.007_bib6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/CMR.05031-11","article-title":"Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain","volume":"25","author":"Ferenczy","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.mcp.2014.11.007_bib7","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.22107","article-title":"Assessment of JC virus DNA in blood and urine from natalizumab-treated patients","volume":"68","author":"Rudick","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.mcp.2014.11.007_bib8","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1099\/vir.0.036798-0","article-title":"Individuals infected with JC polyomavirus do not present detectable JC virus DNA in oropharyngeal fluids","volume":"93","author":"Matos","year":"2012","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.mcp.2014.11.007_bib9","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1099\/vir.0.020115-0","article-title":"Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians","volume":"91","author":"Antonsson","year":"2010","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.mcp.2014.11.007_bib10","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1128\/CVI.05175-11","article-title":"Age-specific seroprevalence of Merkel cell polyomavirus, BK virus, and JC virus","volume":"18","author":"Viscidi","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.mcp.2014.11.007_bib11","series-title":"Viral infect. humans epidemiol. control","article-title":"Polyomaviruses: progressive multifocal leukoencephalopathy and other diseases","author":"Viscidi","year":"2014"},{"key":"10.1016\/j.mcp.2014.11.007_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4137\/JCNSD.S14049","article-title":"Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis","volume":"2014","author":"Hoepner","year":"2014","journal-title":"J\u00a0Cent Nerv Syst Dis"},{"key":"10.1016\/j.mcp.2014.11.007_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/2040622312466279","article-title":"Recent advances in treating multiple sclerosis: efficacy, risks and place in therapy","volume":"4","author":"Jeffery","year":"2013","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.mcp.2014.11.007_bib14","unstructured":"Biogen Idec, Biogen website, http:\/\/www.biogenidec-international.com\/tysabri.aspx?ID=4763."},{"key":"10.1016\/j.mcp.2014.11.007_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13365-012-0080-7","article-title":"Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies","volume":"18","author":"Bellizzi","year":"2012","journal-title":"J\u00a0Neurovirol"},{"key":"10.1016\/j.mcp.2014.11.007_bib16","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.mcp.2014.11.007_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-201781","article-title":"Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab","volume":"2014","author":"Isidoro","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.mcp.2014.11.007_bib18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/2042098612453849","article-title":"Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps","volume":"3","author":"Zaheer","year":"2012","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.mcp.2014.11.007_bib19","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1002\/art.27687","article-title":"A\u00a0case of progressive multifocal leukoencephalopathy in a patient treated with infliximab","volume":"62","author":"Kumar","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mcp.2014.11.007_bib20","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMc1211805","article-title":"PML in a patient treated with fumaric acid","volume":"368","author":"Ermis","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcp.2014.11.007_bib21","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1056\/NEJMc1215357","article-title":"PML in a patient treated with dimethyl fumarate from a compounding pharmacy","volume":"368","author":"van Oosten","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcp.2014.11.007_bib22","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMc1300283","article-title":"Manufacturer's response to case reports of PML","volume":"368","author":"Sweetser","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcp.2014.11.007_bib23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.mcp.2014.11.007_bib24","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1002\/cncr.28712","article-title":"Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project","volume":"120","author":"Carson","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.mcp.2014.11.007_bib25","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/WCO.0b013e328360279f","article-title":"Progressive multifocal leukoencephalopathy in patients with multiple sclerosis","volume":"26","author":"Baldwin","year":"2013","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.mcp.2014.11.007_bib26","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcp.2014.11.007_bib27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/practneurol-2011-000092","article-title":"Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring","volume":"12","author":"Hunt","year":"2012","journal-title":"Pract Neurol"},{"key":"10.1016\/j.mcp.2014.11.007_bib28","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40263-014-0168-0","article-title":"Natalizumab: risk stratification of individual patients with multiple sclerosis","volume":"28","author":"Tur","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.mcp.2014.11.007_bib29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.mcp.2014.11.007_bib30","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","article-title":"A\u00a0second-generation ELISA (STRATIFY JCV\u2122 DxSelect\u2122) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification","volume":"57","author":"Lee","year":"2013","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.mcp.2014.11.007_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/ana.24286","article-title":"Anti-JCV antibody levels in serum or plasma further define risk of natalizumab-associated PML","author":"Plavina","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.mcp.2014.11.007_bib32","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ana.22606","article-title":"Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1","volume":"70","author":"Bozic","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.mcp.2014.11.007_bib33","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1136\/jnnp-2012-304332","article-title":"Changes to anti-JCV antibody levels in a Swedish national MS cohort","volume":"84","author":"Warnke","year":"2013","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.mcp.2014.11.007_bib34","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0b013e3182583022","article-title":"Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort","volume":"78","author":"Trampe","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.mcp.2014.11.007_bib35","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458513477925","article-title":"Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort","volume":"19","author":"Olsson","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.mcp.2014.11.007_bib36","first-page":"2293","article-title":"Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy","volume":"259","author":"Outteryck","year":"2012","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.mcp.2014.11.007_bib37","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ana.23893","article-title":"JC virus antibody status underestimates infection rates","volume":"74","author":"Berger","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.mcp.2014.11.007_bib38","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMc1214233","article-title":"JC viremia in natalizumab-treated patients with multiple sclerosis","volume":"368","author":"Major","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcp.2014.11.007_bib39","doi-asserted-by":"crossref","first-page":"e1004084","DOI":"10.1371\/journal.ppat.1004084","article-title":"JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants","volume":"10","author":"Sundqvist","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.mcp.2014.11.007_bib40","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMc1308784","article-title":"More on JC viremia in natalizumab-treated patients with multiple sclerosis","volume":"369","author":"Subramanyam","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcp.2014.11.007_bib41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2013.05.009","article-title":"Cerebrospinal fluid and serum JC virus antibody detection in multiple sclerosis patients treated with natalizumab","volume":"261","author":"Lin","year":"2013","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.mcp.2014.11.007_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/ana.24153","article-title":"Cerebrospinal fluid JC virus antibody Index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy","author":"Warnke","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.mcp.2014.11.007_bib43","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMoa0904267","article-title":"Asymptomatic reactivation of JC virus in patients treated with natalizumab","volume":"361","author":"Chen","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcp.2014.11.007_bib44","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/jnnp.2009.201079","article-title":"No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study","volume":"81","author":"Rinaldi","year":"2010","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.mcp.2014.11.007_bib45","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S1474-4422(10)70006-5","article-title":"Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study","volume":"9","author":"Jilek","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.mcp.2014.11.007_bib46","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s11481-012-9366-z","article-title":"Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification","volume":"7","author":"Laroni","year":"2012","journal-title":"J\u00a0Neuroimmune Pharmacol"},{"key":"10.1016\/j.mcp.2014.11.007_bib47","first-page":"954","article-title":"JCV detection in multiple sclerosis patients treated with natalizumab","volume":"257","author":"Sadiq","year":"2010","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.mcp.2014.11.007_bib48","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s11481-013-9496-y","article-title":"Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish Multiple Sclerosis patients treated with natalizumab","volume":"8","author":"Dominguez-Mozo","year":"2013","journal-title":"J\u00a0Neuroimmune Pharmacol"},{"key":"10.1016\/j.mcp.2014.11.007_bib49","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jviromet.2004.06.021","article-title":"Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid","volume":"121","author":"Ryschkewitsch","year":"2004","journal-title":"J\u00a0Virol Methods"},{"key":"10.1016\/j.mcp.2014.11.007_bib50","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/1479-5876-10-248","article-title":"JC virus detection and JC virus-specific immunity in natalizumab-treated multiple sclerosis patients","volume":"10","author":"Mancuso","year":"2012","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.mcp.2014.11.007_bib51","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/ana.24148","article-title":"JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis","volume":"75","author":"Chalkias","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.mcp.2014.11.007_bib52","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/1743-422X-10-298","article-title":"Human polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study","volume":"10","author":"Bellizzi","year":"2013","journal-title":"Virol J"},{"key":"10.1016\/j.mcp.2014.11.007_bib53","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/infdis\/jir198","article-title":"Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity","volume":"204","author":"Gorelik","year":"2011","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.mcp.2014.11.007_bib54","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/infdis\/jir256","article-title":"Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients","volume":"204","author":"Reid","year":"2011","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.mcp.2014.11.007_bib55","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1128\/JVI.00131-13","article-title":"Immunological hallmarks of JC virus replication in multiple sclerosis patients on long-term natalizumab therapy","volume":"87","author":"Hendel-Chavez","year":"2013","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.mcp.2014.11.007_bib56","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1212\/01.wnl.0000327671.91357.96","article-title":"Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis","volume":"71","author":"Krumbholz","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.mcp.2014.11.007_bib57","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jneuroim.2011.02.010","article-title":"Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients","volume":"235","author":"Skarica","year":"2011","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.mcp.2014.11.007_bib58","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000302687","article-title":"Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells","volume":"63","author":"Putzki","year":"2010","journal-title":"Eur Neurol"},{"key":"10.1016\/j.mcp.2014.11.007_bib59","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/bmt.2010.328","article-title":"CD49d blockade by natalizumab therapy in patients with multiple sclerosis increases immature B-lymphocytes","volume":"46","author":"Lesesve","year":"2011","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.mcp.2014.11.007_bib60","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/eji.201142108","article-title":"Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis","volume":"42","author":"Planas","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.mcp.2014.11.007_bib61","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1001\/jamaneurol.2014.1858","article-title":"Relevance of CD34+ cells as a reservoir for JC virus in patients with multiple sclerosis\u2013reply","volume":"71","author":"Frohman","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.mcp.2014.11.007_bib62","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamaneurol.2014.63","article-title":"JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab","volume":"71","author":"Frohman","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.mcp.2014.11.007_bib63","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/1352458510385834","article-title":"CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus","volume":"17","author":"Warnke","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.mcp.2014.11.007_bib64","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1128\/JVI.03221-13","article-title":"Lymphocyte gene expression and JC virus noncoding control region sequences are linked with the risk of progressive multifocal leukoencephalopathy","volume":"88","author":"Marshall","year":"2014","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.mcp.2014.11.007_bib65","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1212\/WNL.0b013e3182a351fb","article-title":"L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients","volume":"81","author":"Schwab","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.mcp.2014.11.007_bib66","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1212\/WNL.0b013e3182a352a6","article-title":"Risk factors for rare diseases can be risky to define: PML and natalizumab","volume":"81","author":"Major","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.mcp.2014.11.007_bib67","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1352458511435105","article-title":"Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab","volume":"18","author":"S\u00f8rensen","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.mcp.2014.11.007_bib68","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/597126","article-title":"Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors","volume":"199","author":"Egli","year":"2009","journal-title":"J\u00a0Infect Dis"}],"container-title":["Molecular and Cellular Probes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890850814000656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890850814000656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T01:42:02Z","timestamp":1566092522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890850814000656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0890850814000656"],"URL":"https:\/\/doi.org\/10.1016\/j.mcp.2014.11.007","relation":{},"ISSN":["0890-8508"],"issn-type":[{"value":"0890-8508","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Probes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcp.2014.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}